Manifold Bio is a pioneering therapeutics company that specializes in the design of precision biologics. The company operates in the pharmaceutical industry, specifically in the area of drug design and development. Their unique selling point is their innovative in vivo drug design platform, which is the first of its kind in the world. In vivo, a term that means 'within the living', refers to testing done inside a living organism, as opposed to in a lab dish or test tube.

Manifold Bio's platform is powered by their proprietary mCodes™ technology, a novel protein barcoding system. This technology allows for protein multiplexing, which is the simultaneous study of multiple proteins in a single experiment. This is particularly useful for testing complex biologics, which are large molecule drugs derived from living organisms, in a pooled in vivo setting.

The company recently raised $40 million in a Series A funding round, which they plan to use to expand their in vivo biologics design platform. This indicates a strong market interest in their technology and potential for growth.

Manifold Bio's business model is likely based on the development and licensing of their drug design platform and technologies to other pharmaceutical companies. They may also generate revenue from partnerships and collaborations for the development of new therapeutics.

Their clients are likely to be other companies in the pharmaceutical and biotech industries, particularly those involved in the development of complex biologics and protein therapeutics.

Keywords: Therapeutics, Precision Biologics, In Vivo Drug Design, Protein Barcoding, mCodes™ Technology, Protein Multiplexing, Complex Biologics, Pharmaceutical Industry, Drug Development, Biotech.